Accordingly, a novel dual inhibitor of cMET and PD1 has shown superior anti-tumor efficacy with solid anti-proliferative and anti-metastatic effects compared to monotherapy with PD1 inhibitors alone in tumor cell lines and in a mouse model with liver cancer (65). This evidence concerns the gene PDCD1 and liver cancer.